BioLineRx (NASDAQ:BLRX) Stock Price Crosses Above 200 Day Moving Average – Here’s What Happened

Shares of BioLineRx Ltd. (NASDAQ:BLRXGet Free Report) crossed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $5.10 and traded as high as $6.45. BioLineRx shares last traded at $5.74, with a volume of 966,365 shares.

Analysts Set New Price Targets

Several equities analysts recently commented on BLRX shares. Wall Street Zen started coverage on shares of BioLineRx in a research note on Sunday, May 18th. They set a “sell” rating for the company. HC Wainwright restated a “buy” rating on shares of BioLineRx in a report on Wednesday, May 28th. Finally, Jones Trading raised shares of BioLineRx from a “hold” rating to a “strong-buy” rating in a research report on Friday, May 30th.

Read Our Latest Stock Report on BLRX

BioLineRx Price Performance

The company has a market cap of $19.11 million, a price-to-earnings ratio of -0.65 and a beta of 1.29. The company has a current ratio of 1.52, a quick ratio of 1.37 and a debt-to-equity ratio of 2.11. The company has a fifty day moving average price of $3.34 and a two-hundred day moving average price of $5.10.

BioLineRx (NASDAQ:BLRXGet Free Report) last issued its earnings results on Tuesday, May 27th. The biotechnology company reported $1.39 EPS for the quarter, topping the consensus estimate of ($0.84) by $2.23. The firm had revenue of $11.75 million during the quarter, compared to analysts’ expectations of $7.72 million. BioLineRx had a negative return on equity of 163.37% and a negative net margin of 90.57%. As a group, equities research analysts anticipate that BioLineRx Ltd. will post -5.8 EPS for the current fiscal year.

Hedge Funds Weigh In On BioLineRx

An institutional investor recently bought a new position in BioLineRx stock. Highbridge Capital Management LLC purchased a new position in BioLineRx Ltd. (NASDAQ:BLRXFree Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 1,010,012 shares of the biotechnology company’s stock, valued at approximately $215,000. Highbridge Capital Management LLC owned approximately 50.50% of BioLineRx as of its most recent SEC filing. 1.56% of the stock is currently owned by institutional investors and hedge funds.

About BioLineRx

(Get Free Report)

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.

See Also

Receive News & Ratings for BioLineRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx and related companies with MarketBeat.com's FREE daily email newsletter.